RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CTI Biopharma Stock

CTI Biopharma ROCE 2025

CTI Biopharma ROCE

4.54

Ticker

CTIC

ISIN

US12648L6011

WKN

A2DJWX

In 2025, CTI Biopharma's return on capital employed (ROCE) was 4.54, a 0% increase from the 0 ROCE in the previous year.

CTI Biopharma Aktienanalyse

What does CTI Biopharma do?

CTI Biopharma Corp is a biopharmaceutical company focused on the development of therapies for the treatment of cancer and other serious diseases. The company was founded in 1991 in Seattle, USA, and has been listed on the NASDAQ stock exchange since 1997. History: The history of CTI Biopharma Corp dates back to 1996 when the company launched its first product, a treatment for chronic myeloid leukemia. Since then, the company has continuously evolved and grown through the acquisition of other companies. In 2014, CTI Biopharma Corp merged with the French companies Cell Therapeutics, and in 2015, it acquired the Italian company Chroma Therapeutics. Business model: CTI Biopharma Corp's business model focuses on the development and commercialization of cancer therapies. The company utilizes its expertise in biology, chemistry, and medicine to develop innovative therapies that target specific molecular targets in tumors. The therapies are developed and produced by CTI Biopharma Corp itself before being distributed by doctors and healthcare facilities. Different divisions: The different divisions of CTI Biopharma Corp focus on various areas of cancer research. The "Hematology" division investigates the treatment of blood diseases such as leukemia and lymphomas. "Oncology," on the other hand, deals with the treatment of solid tumors such as breast cancer and lung cancer. Additionally, CTI Biopharma Corp also works in the field of "Toxicology" by studying the compatibility of medications and their effects on the immune system. Products: CTI Biopharma Corp offers a variety of products, but its flagship product Pixuvri is considered the most outstanding. Pixuvri is a chemotherapy drug used for the treatment of aggressive B-cell non-Hodgkin lymphomas (NHL). The drug is already approved in Europe, where it has been marketed since 2012. Pixuvri is currently under evaluation by the Food and Drug Administration (FDA) for potential introduction into the US market. Another product from CTI Biopharma Corp is Pacritinib, a tablet form used for the treatment of myelofibrosis. Conclusion: CTI Biopharma Corp has specialized in the development of drugs for the treatment of cancer and other diseases over the years. The company has focused on different divisions such as oncology and toxicology and offers a variety of products, including Pixuvri and Pacritinib. The acquisition of Chroma Therapeutics and Cell Therapeutics further highlights CTI Biopharma Corp's expansion strategy. CTI Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling CTI Biopharma's Return on Capital Employed (ROCE)

CTI Biopharma's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing CTI Biopharma's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

CTI Biopharma's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in CTI Biopharma’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about CTI Biopharma stock

What is the ROCE (Return on Capital Employed) of CTI Biopharma this year?

The ROCE of CTI Biopharma is 4.54 undefined this year.

How has the ROCE (Return on Capital Employed) of CTI Biopharma developed compared to the previous year?

The ROCE of CTI Biopharma has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of CTI Biopharma?

A high Return on Capital Employed (ROCE) indicates that CTI Biopharma has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of CTI Biopharma?

A low ROCE (Return on Capital Employed) can indicate that CTI Biopharma has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from CTI Biopharma impact the company?

An increase in the ROCE of CTI Biopharma can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of CTI Biopharma affect the company?

A decrease in ROCE of CTI Biopharma can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of CTI Biopharma?

Some factors that can affect CTI Biopharma's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of CTI Biopharma so important for investors?

The ROCE of CTI Biopharma is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can CTI Biopharma take to improve the ROCE?

To improve the ROCE, CTI Biopharma can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does CTI Biopharma pay?

Over the past 12 months, CTI Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CTI Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of CTI Biopharma?

The current dividend yield of CTI Biopharma is .

When does CTI Biopharma pay dividends?

CTI Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CTI Biopharma?

CTI Biopharma paid dividends every year for the past 0 years.

What is the dividend of CTI Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CTI Biopharma located?

CTI Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von CTI Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CTI Biopharma from 1/24/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/24/2025.

When did CTI Biopharma pay the last dividend?

The last dividend was paid out on 1/24/2025.

What was the dividend of CTI Biopharma in the year 2024?

In the year 2024, CTI Biopharma distributed 0 USD as dividends.

In which currency does CTI Biopharma pay out the dividend?

The dividends of CTI Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CTI Biopharma

Our stock analysis for CTI Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CTI Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.